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Abstract
Background: The phenazines are redox-active secondary metabolites that a large number of bacterial strains
produce and excrete into the environment. They possess antibiotic activity owing to the fact that they can reduce
molecular oxygen to toxic reactive oxygen species. In order to take advantage of this activity, phenazine producers
need to protect themselves against phenazine toxicity. Whereas it is believed that phenazine-producing
pseudomonads possess highly active superoxide dismutases and catalases, it has recently been found that the
plant-colonizing bacterium Enterobacter agglomerans expresses a small gene ehpR to render itself resistant towards
D-alanyl-griseoluteic acid, the phenazine antibiotic produced by this strain.
Results: To understand the resistance mechanism installed by EhpR we have determined its crystal structure in the
apo form at 2.15 Å resolution and in complex with griseoluteic acid at 1.01 Å, respectively. While EhpR shares a
common fold with glyoxalase-I/bleomycin resistance proteins, the ligand binding site does not contain residues
that some related proteins employ to chemically alter their substrates. Binding of the antibiotic is mediated by π-
stacking interactions of the aromatic moiety with the side chains of aromatic amino acids and by a few polar
interactions. The dissociation constant KD between EhpR and griseoluteic acid was quantified as 244 ± 45 μM by
microscale thermophoresis measurements.
Conclusions: The data accumulated here suggest that EhpR confers resistance by binding D-alanyl-griseoluteic
acid and acting as a chaperone involved in exporting the antibiotic rather than by altering it chemically. It is
tempting to speculate that EhpR acts in concert with EhpJ, a transport protein of the major facilitator superfamily
that is also encoded in the phenazine biosynthesis operon of E. agglomerans. The low affinity of EhpR for
griseoluteic acid may be required for its physiological function.
Background
Newly emerging resistance against antibiotics is an
increasing problem in the treatment of infectious dis-
ease. The situation is currently worsening at such an
alarming speed that the World Health Organization
decided to bring it to the spotlight by making it the
topic of World Health Day in 2011 [1]. In order to over-
come resistance, create opportunities for the
development of novel antibiotics or enable the contin-
ued use of existing compounds, it is important to under-
stand resistance mechanisms at the molecular level.
These mechanisms are highly versatile, from simple
mutation of the antibiotic’s target to development of
mechanisms to reduce uptake by the infectious organ-
ism or the installation of factors that destroy or in other
ways deactivate the antibiotic [2]. The latter is usually
achieved by horizontal gene transfer, e.g. through trans-
mission of plasmids or transposons that carry resistance
genes from one strain to the next.
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On the other hand, a large number of antibiotics are
produced by microorganisms themselves, which secrete
these into the environment to compete with other spe-
cies that colonize the same habitat. In the case of com-
pounds with nonspecific toxicity, such as those that give
rise to reactive oxygen species (ROS), the producing
strain is faced with the problem of having to avoid self-
poisoning. This cannot be resolved by simply destroying
the antibiotic as this would contradict the purpose of
synthesizing these toxins in the first place and would
lead to a waste of metabolic energy instead.
One example of antibiotics with nonspecific toxicity
are the phenazines, a class of bacteria-produced antibio-
tics that has gained increasing attention in recent years
[3]. They comprise a group of over 100 compounds iso-
lated from natural sources and several thousand deriva-
tives that have been synthesized by chemical methods
[4,5]. In addition to being able to intercalate DNA and
inhibit topoisomerases, phenazines act through their
redox activity, which enables them to exchange elec-
trons with e.g. NADH, Fe2+/Fe3+ or molecular oxygen.
Whereas the reoxidation of NADH may play an impor-
tant role in the survival of phenazine producers in
anoxic environments, like those found in the deeper
layers of biofilms, the reduction of ferric iron or O2
directly or indirectly leads to the generation of toxic
ROS. This explains the broad specificity antibiotic activ-
ity of phenazines and also their function as virulence
factors in infectious disease. For example, the blue phe-
nazine derivative pyocyanin (5-N-methyl-1-hydroxyphe-
nazium betaine) induces tissue damage in patients
infected with a well-studied Gram-negative phenazine
producer Pseudomonas aeruginosa [6,7] and it has been
demonstrated that the immune system can clear P. aer-
uginosa infections significantly more easily if phenazine
biosynthesis is impaired [8].
It has been shown that P. aeruginosa increases the
production of iron- and manganese-dependent superox-
ide dismutases as well as catalase in response to pyocya-
nin, hence protecting itself from phenazines by
deactivating ROS [9]. A different mechanism of phena-
zine self-resistance has recently been discovered in the
plant-colonizing bacterium Enterobacter agglomerans
(previously termed Pantoea agglomerans and Erwinia
herbicola) strain Eh1087. This strain is capable of con-
trolling fireblight, a plant disease caused by the phyto-
pathogen Erwinia amylovora [10], by producing the
phenazine derivative D-alanylgriseoluteic acid (AGA)
from genes carried on a 200 kB plasmid. AGA is also
active against a number of other bacteria, including
clinically relevant species such as Staphylococcus aureus
[11]. It has also been isolated from a marine Vibrio spe-
cies (SANK 73794) [12] and most likely is produced
from griseoluteic acid (GA; 6-(hydroxymethyl)-9-
methoxyphenazine-1-carboxylic acid), a compound that
has also been found in Pelagiobacter variabilis [13] and
more recently in an Indonesian Streptomyces sp.
(ICBB8198) [14]. The genetic material required for AGA
biosynthesis is assembled in an operon that contains the
15 open reading frames ehpA-O and is in part highly
similar to the conserved phz-operon found in Pseudo-
monas and other phenazine producing species. Of the
encoded enzymes, EhpA-E utilize chorismic acid to pro-
duce phenazine-1,6-dicarboxylic acid (PDC) [4], which is
then converted to AGA by the remaining enzymes
EhpF-O [10,15] with the exception of EhpJ, which
encodes a membrane transporter of the major facilitator
superfamily presumably involved in exporting AGA
from the cell. In addition to the genes involved in AGA
biosynthesis, the promoter of the ehp-operon also trig-
gers the transcription of an additional gene ehpR from
the second DNA strand (Figure 1). This gene encodes a
protein of 129 amino acids and has been shown to give
rise to resistance against AGA but not some other com-
mon phenazines like phenazine-1-carboxylic acid. When
first reported in 2002, no sequence homology to other
proteins could be detected [10]. In order to investigate
the molecular mechanisms behind EhpR-mediated phe-
nazine resistance, we have therefore characterized the
protein and its interaction with the E. agglomerans-pro-
duced phenazine derivative griseoluteic acid. Our data
suggest that EhpR acts as a binding protein that escorts
AGA to a membrane transporter for subsequent
secretion.
Results
EhpR belongs to the glyoxalase I/bleomycin resistance
protein family
Analysis of the EhpR sequence with the fold recognition
engine PHYRE [16] unequivocally assigns EhpR as
belonging to the glyoxalase I/bleomycin resistance pro-
tein family. These proteins form a very large group
whose members act as modifying enzymes or as binders
that render toxic compounds harmless, sometimes in a
metal-dependent manner. A recent sequence similarity
search in April 2011 with EhpR against the Protein Data
Bank [17], on the other hand, returns only one structure
with an E-value below 0.5 (PDB entry 2KJZ; Lemak et
al., Northeast Structural Genomics Consortium, unpub-
lished; uncharacterized protein ATC0852 from Agrobac-
terium tumefaciens, 29% sequence identity to EhpR)
despite the fact that several dozens of proteins from this
family have been investigated by structural methods.
Closer inspection of these structures reveals, however,
that EhpR does not possess the catalytic motifs or bind-
ing residues that many of the structurally related and
functionally characterized proteins utilize to interact
with their substrates. This indicates that EhpR belongs
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to a distant and unexplored branch of this otherwise
well-studied protein family.
Structure of EhpR
EhpR behaved as a homodimer during size exclusion
chromatography and crystallized in space group P212121
with two and one dimers per asymmetric unit in the
apo and GA-cocrystallized form, respectively. The struc-
ture was solved from single-wavelength anomalous dif-
fraction data collected at the K-edge of seleno-L-
methionine labeled protein crystallized in the apo form.
These crystals diffracted to 2.15 Å and the structure was
refined to a crystallographic R-factor of 20.5% with Rfree
= 25.9%. Cocrystallization with GA gave rise to highly
improved crystals under the same conditions. Data were
collected to 1.01 Å and the final model has an R-factor
or 12.6% with Rfree = 14.6% (Table 1).
The EhpR monomer consists of two babb’b fold units
(’ indicating antiparallel orientation with respect to the
other strands) that are typical for members of the glyox-
alase I/bleomycin resistance protein family. Because of
this internal symmetry within the monomer, there are
two principal ways of forming the dimer, which can be
distinguished by the interaction of a-helices from two
modules. These a-helices either contact each other
within the monomer or at the monomer/monomer
interface [18]. In EhpR, the helices interact within the
monomer and this leads to the formation of two 8-
stranded b-sheets that are each made up from two
babb’b units where each monomer contributes one unit
(Figure 2A-C). This generates two conspicuous half-b-
barrels that contain the ligand binding or active sites of
EhpR and related proteins. Also noteworthy in the EhpR
dimer are the extended N-termini, which give rise to an
“arm exchange” between the two monomers. While
these arms are too flexible to be traced beyond G6 in
the apo structure, all residues including those remaining
from the N-terminal His6-tag after thrombin cleavage
could be traced in the atomic resolution data set. In this
structure the N-termini extend far beyond the fold core
and have the appearance of “antennae”. It is tempting to
speculate that they may be required for the function of
EhpR in providing resistance towards self-produced
phenazines.
A DALI search [19] for similar structures in the Protein
Data Bank PDB [17] retrieves more than 60 different pro-
teins, many of which have not been characterized func-
tionally. The structure-derived sequence identity of EhpR
to these entries is generally below 20%, showing that
EhpR stems from another part of the family tree that has
not been investigated to date. The most similar structure
is the fosfomycin resistance protein FosA from transpo-
son Tn2921 (PDB entry 1NPB) [20] with an rmsd of 2.2
Å for 116 residues and a sequence identity of 14%. FosA
is a metal-dependent hydrolase, and the residues required
for its activity are not conserved in EhpR.
Binding of griseoluteic acid
Interaction studies were performed with griseoluteic
acid (GA) since D-alanylgriseoluteic acid was not avail-
able in sufficient quantities for this study. While it was
not possible to detect binding of GA by isothermal titra-
tion calorimetry, a time-dependent decrease of protein
tryptophan fluorescence in a stopped-flow experiment
indicated interaction between GA and EhpR. However,
the signal could not be saturated with a large excess of
GA (250 or 500 μM GA vs. 5 μM EhpR), indicating that
the interaction is relatively weak (Figure 3A). This was
confirmed in microscale thermophoresis measurements,
where the dissociation constant KD between fluorescein-
labeled EhpR and GA was quantified as 244 ± 45 μM
(Figure 3B).
Figure 1 Phenazine biosynthesis in Enterobacter agglomerans Eh1087. The phenazine biosynthesis operon of E. agglomerans Eh1087
contains 16 open reading frames, which are required to convert chorismic acid to phenazine-1,6-dicarboxylic acid (PDC; light grey) and further
to D-alanyl griseoluteic acid (AGA; dark grey). EhpR (red) mediates resistance to self-produced AGA. It likely acts as a shuttle that delivers AGA to
the major facilitator membrane transporter EhpJ (blue).
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Preincubation with GA nevertheless led to highly
improved crystals and additional electron density reveals
the presence of GA in one of the ligand binding sites
(Figure 3C). In contrast to the apo structure, which
crystallized with two EhpR dimers in the asymmetric
unit, the asymmetric unit of GA-cocrystallized EhpR
contains only one dimer despite having been obtained
with the same precipitant. The occupied ligand binding
site resides in an area of crystal contacts, but neighbor-
ing molecules do not directly contribute to GA binding.
The very high resolution of the ligand complex reveals
details that are not discernable in the apo structure, e.g.
alternative orientations of several backbone carbonyl
groups and the presence of two alternative traces in
Y105 - T106 (not shown).
In common with other proteins of this enzyme family
the ligand binding sites of EhpR are located in the half-
barrels that form from b-strands of both monomers. In
EhpR, the binding site adopts the shape of a cleft (Figure
2D), and the interactions with GA involve hydrogen
bonds between GA’s carboxylate group and the side
chains of R42 and W57 together with water-mediated
contacts of the hydroxyl group with the side chain of Y43
and the carbonyl of L128* (* indicating residues of the
second monomer, Figure 4A). A large contribution to
complex formation seemingly results from a π-stacking
interaction of the phenazine ring system with the side
chain of Y43. Similar to EhpR, binding through π-stack-
ing is also found in the related mitomycin C binding pro-
tein from Streptomyces lavendulae (PDB entry 1KLL),
where two aromatic side chains hold the ligand in a
clamp-like fashion [21] (Figure 4B). Indeed, in EhpR the
phenyl ring of F109* is located on the opposite face of
the phenazine moiety, yet the position and orientation is
Table 1 Data collection and refinement statistics
Se-SAD2 EhpR apo Ehpr/GA complex
Data collection1
Space group P212121 P212121 P212121
Cell dimensions
a, b, c (Å)







Wavelength 0.979147 0.934 0.934
f’ (electrons) -8.2 - -
f’’ (electrons) 5.1 - -
Resolution (Å)3 20 - 2.7 (2.8 - 2.7) 20 - 2.15 (2.25 - 2.15) 20 - 1.01 (1.11 - 1.01)
Rsym(I) (%)
4 13.7 (52.8) 5.0 (35.9) 4.0 (35.9)
Rmerge(F) (%)
5 7.3 (33.4) 5.6 (29.4) 6.4 (36.6)
< I/s(I) > 15.3 (4.2) 23.0 (5.1) 19.0 (4.0)
Completeness (%) 99.7 (100) 98.1 (92.5) 98.5 (95.5)
Redundancy 7.7 (7.6) 6.8 (5.0) 4.3 (3.1)
Refinement
Resolution (Å) 20 - 2.15 (2.20 - 2.15) 20 - 1.01 (1.02 - 1.01)
No. reflections 26266 (1800) 125498 (3663)
Rwork (%) 20.5 (29.2) 12.6 (23.7)






Bond lengths (Å) 0.020 0.022
Bond angles (°) 1.733 2.085
PDB entry code 3SK1 3SK2
1All data sets were collected from single crystals.
2Data collections statistics for MAD data refer to unmerged Friedel pairs.
3Values in parentheses refer to the highest resolution shell.
4Rsym(I) = (Σhkl Σi |I(h)j - <I(h)>|)/(Σhkl Σi I(h)j), where I(h)j is the measured diffraction intensity, <I(h)> is its average and the summation includes all observations.
5Rmerge(F) = (Σhkl SQRT (n/(n - 1)) Σi |F(h)j - <F(h)>|)/(Σhkl Σi F(h)j) is a redundancy-independent merging R-factor of structure factor amplitudes. Symbols and
indices are analogous to those in the calculation of Rsym, n is the number of observations of reflection h and SQRT indicates the square root [43].
6The contribution of TLS parameters to B-factors of the EhpR apo structure has been removed with TLSANL [44].
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not optimal for π-stacking with the ligand. While the apo
and complex structure are otherwise highly similar (aver-
age rmsd < 0.6 Å over the complete monomer), F109*
undergoes a significant conformational and positional
change on ligand binding. It adopts a different rotamer
and moves together with the loop from E103 to G110,
which leads to the formation of an open conformation of
the ligand binding site with respect to the apo structure.
This movement is required to unblock the binding site
and suggests that ligand binding follows a multi-step
mechanism. These steps could, however, not be resolved
in the stopped-flow experiments carried out in this study,
since all time traces could satisfyingly be fitted to single
exponentials (not shown).
Structural changes in the loop from E103 to G110
establish new crystal contacts, which explains the gen-
eration of a new crystal lattice in the cocrystallization
experiment (Figure 4A). Other ligand-induced changes
involve the C-terminal residue D129, which becomes
partially disordered on ligand binding.
Only one binding site was occupied in the structure
obtained by cocrystallization. The other center remains
blocked by the side chains of V108 and F109, which
adopt the same conformation as in the apo structure
here. It is not clear at present if this non-symmetrical
behavior is the consequence of anti-cooperativity
between the two binding sites or results from the weak
binding between EhpR and GA, which may require
additional stabilization of the open conformation by the
newly established crystal contacts mentioned above.
Discussion
The investigation of resistance mechanisms against self-
synthesized broad-spectrum antibiotics in microorganisms
Figure 2 Overall structure of EhpR. (A-C) Three perpendicular views of the EhpR homodimer. Each monomer consists of two similar domains,
shown in magenta and pink for one chain. The N-termini are arm-exchanged between the two chains and form extended antennae that are
only visible in the high-resolution EhpR/griseoluteic acid complex (dark grey). Griseoluteic acid is shown in ball-and-stick representation, residues
left behind after thrombin removal of the N-terminal His6-tag used for affinity purification are shown in white. (D) Molecular surface around the
griseoluteic acid binding site, colored by electrostatic potential calculated with APBS [42]. The D-alanyl moiety of AGA has been modeled (grey).
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is an interesting field of study because it can provide
insight into how resistance against these compounds may
emerge even before they are applied in the clinic. In this
study, we have analyzed the phenazine resistance protein
EhpR from Enterobacter agglomerans Eh1087, a strain that
can be employed for biological control of bacteria-induced
disease in several economically important plants.
The crystal structure of EhpR demonstrates that the
protein belongs to the family of glyoxalase I/bleomycin
resistance proteins. Even though it possesses only low
sequence homology to the better studied members of
this family, the atomic resolution crystal structure of
EhpR in complex with griseoluteic acid shows that the
protein shares common principles with mitomycin C
and bleomycin resistance protein in binding the antibio-
tic, namely a π-stacking sandwich interaction to hold
the flat aromatic molecule (Figure 4A/B). Because the
binding site does not contain residues that catalyze che-
mical conversion in other related proteins like glyoxalase
I or fosfomycin resistance protein FosA/X, EhpR most
likely acts as a chaperone involved in the secretion of
phenazine antibiotics produced by P. agglomerans. It is
tempting to speculate that the cognate transporter of
EhpR is EhpJ, which is a major facilitator superfamily
transport protein also encoded within the phenazine
biosynthesis operon of this strain (Figure 1) [10].
It is interesting that the binding of GA is relatively
weak. While we presently cannot exclude that AGA
binds more tightly, a model of this complex based on
the structure with GA argues against this because the
D-alanyl group projects to the surface of EhpR with no
strong interactions discernable (Figure 2D). In addition,
Figure 3 Griseoluteic acid binds EhpR. (A) Stopped-flow transient kinetic measurements demonstrate binding of griseoluteic acid to EhpR.
Incubation of EhpR (5 μM) with an excess of griseoluteic acid (black circle: 250 μM; black triangle: 500 μM) leads to a time-dependent decrease
of tryptophan fluorescence, whereas no change is observed in the absence of griseoluteic acid (cross) or EhpR (empty circle). (B) Microscale
thermophoresis measurements of 25 nM fluorescein-labeled His6-EhpR incubated with the indicated amounts of griseoluteic acid. The relative
fluorescence in the thermophoresis phase of the experiment has been plotted against the concentration of the ligand. (C) Stereo plot of |FO-FC|
difference electron density at the ligand binding site of the high-resolution EhpR/griseoluteic acid (GA) complex before incorporation of the
ligand, displayed at 3.5 s.
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the finding that the binding site is blocked by F109 in
the apo structure indicates that the ligand needs to
induce structural rearrangements. This will also make
binding more difficult than in the related mitomycin C
and bleomycin resistance proteins, whose binding sites
are not blocked in the unliganded form (compare e.g.
PDB entries 1KLL and 1KMZ, [21]). In accordance with
this, the reported dissociation constants for mitomycin
C resistance protein and its ligands are between 6.3 and
31 μM [21], approximately one order of magnitude
smaller than the KD between EhpR and GA measured
here. Weak binding may be a desired property of EhpR,
Figure 4 Interactions between griseoluteic acid and EhpR. (A) Stereo figure of the ligand binding site of EhpR with bound griseoluteic acid
(GA). An asterisk indicates residues from the second monomer. Amino acids that block binding in unoccupied binding sites of the apo and
complex structure (V108, F109) have been superimposed and are shown in thin black lines. Residues from a crystallographic neighboring molecule
are shown in thin white lines. (B) Ligand binding site of mitomycin C resistance protein MRD from Streptomyces lavendulae in complex with 1,2-cis-
1-hydroxy-2,7-diaminomitosene (1-OH-DAM; PDB entry 1KLL[21]). This related protein binds its ligand through a similar π-stacking as EhpR. (C)
Aromatic side chains in the potential ligand binding site of the uncharacterized Pseudomonas aeruginosa protein PA1353 (PDB entry 1U6L).
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since the protein also needs to be able to release its
ligands once it reaches the membrane exporter and the
affinity needs to be tuned to the intracellular AGA con-
centration in E. agglomerans to ensure efficient shuttling
of the antibiotic. While the intracellular concentration
of AGA is not known, other phenazine producers gener-
ate high amounts of phenazines and can be optimized to
produce several grams of phenazines per liter of culture
(corresponding to > 10 mM concentration) [22], indicat-
ing that the low affinity for GA observed here may just
be optimal for the hypothesized chaperone function of
EhpR.
Finally, the interaction between GA and EhpR seems
relatively nonspecific, with only a few hydrogen bonds
being formed between the protein and the compound.
This has also been noted for mitomycin C resistance
protein MRD [21] and it will be interesting to study
whether EhpR can also bind other aromatic molecules
and export them from the cell. Because of this antici-
pated non-specificity, it is also possible that related pro-
teins in other microorganisms can render these strains
resistant to phenazines. In this respect, it is interesting
to note that the genome of the well-studied phenazine
producer Pseudomonas aeruginosa encodes over 20 pro-
teins of this family. The structures of four of these pro-
teins have been determined, but with the exception of
fosfomycin resistance protein PA1129 (PDB entry
1NNR) [23], their functions have not been investigated
experimentally (P. aeruginosa genes PA1353, PA1358
and PA2721 with PDB entries 1U6L, 1U7I and 1U69
[24], all deposited by structural genomics centers). How-
ever, since some of these uncharacterized proteins pos-
sess the two aromatic residues required for the π-
stacking sandwich binding of aromatic ligands (Figure
4C), they may be capable of binding phenazines and
other related aromatic compounds. This may provide a
means of resistance that works in addition to the
increase in superoxide dismutase and catalase activity
described previously [19]. The low specificity of these
binders may also provide a basis for the rapid develop-
ment of new resistance. In this regard, it is interesting
to note that mitomycin C-binding proteins from Strepto-
myces spp. have been found to also bind the structurally
unrelated bleomycin, which is kept in an inactive state
by a related yet metal-dependent protein in bleomycin-
producing streptomycetes [25]. Clearly, this aspect will
have to be investigated further.
Conclusions
Enterobacter agglomerans strain Eh1087 generates the
phenazine antibiotic D-alanyl griseoluteic acid to com-
pete with other microorganisms in its habitat. In order
to protect itself against the toxic action of this com-
pound, the bacterium produces the resistance protein
EhpR together with enzymes required for phenazine bio-
synthesis. EhpR belongs to the glyoxalase I/bleomycin
resistance protein family, whose members have a wide
variety of functions extending from simple binding of
toxic small molecules to their chemical conversion
through enzymatic activity. The structure of EhpR in
complex with griseoluteic acid suggests that it probably
acts as a binder that works in tandem with a mem-
brane-spanning exporter protein. This exporter may be
EhpJ, which is also found in the phenazine biosynthesis
operon of E. agglomerans. A relatively weak affinity for
griseoluteic acid presumably reflects a high level of phe-
nazines generated by this strain. Because the interaction
between ligand and protein relies on relatively unspecific
interactions, mainly consisting of π-stacking with two
aromatic amino acids, EhpR may be capable of binding
other aromatic compounds, and related proteins from
other species may be able to bind phenazine derivatives.
Methods
Production of recombinant EhpR
ehpR (UniProtKB entry Q8GPH6) was amplified from a
pBluescript plasmid with primers ehpR-for (5’-
GGACCTCCATATGACTGATCTAGCTGGCCC-3’)
and ehpR-rev (5’-TTGGATCCTCAATCAAGCGGGCA-
GACC-3’) and then cloned into pET15b (Merck Bios-
ciences). Heterologous expression employed E. coli
Rosetta pLysS [DE3] (Merck Biosciences) in LB medium
at 37°C induced with 1 mM IPTG. The protein was pur-
ified on immobilized Ni2+, using HiTrap chelating resin,
followed by cleavage of the N-terminal His6-tag with
thrombin and final size exclusion chromatography on
Superdex S75 (GE Healthcare) equilibrated with 20 mM
TRIS-HCl pH 8.0, 150 mM NaCl. Fractions containing
pure protein were pooled, concentrated to 20 mg/ml
and stored at -80°C until further usage.
Seleno-L-methionine labeling was achieved by sup-
pressing methionine biosynthesis in synthetic media
supplemented with Se-L-methionine [26].
Crystallization, data collection, structure solution and
refinement
Initial crystallization conditions were determined with
Crystal Screen and Crystal Screen 2 from Hampton
Research. The optimized setup consisted of a hanging
drop of 1 μl protein solution at 20 mg/ml EhpR mixed
with 1 μl reservoir (27 - 30% PEG 4000, 0.2 M ammo-
nium acetate, 0.1 M sodium citrate pH 5.6) equilibrated
against 500 μl reservoir at room temperature. Crystals
of the seleno-L-methionine labeled protein were
obtained under similar conditions. For cocrystallization
with griseoluteic acid, a suspension of the ligand at a
nominal concentration of 5 mM was prepared in 100
mM TRIS-HCl pH 8.5 and then mixed 1:1 with protein
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solution at 40 mg/ml EhpR on ice for one hour. Griseo-
luteic acid was prepared as described previously [10].
Diffraction data were collected at 100 K at beamlines
ID14EH2, ID14EH3 and ID29 of the European Synchro-
tron Radiation facility (ESRF Grenoble, France). Cryo-
protection was not required. All data were indexed,
integrated and scaled with the XDS package [27]. The
structure of the apo form was solved from SAD data
collected at the K-absorption edge of a crystal prepared
from seleno-L-methionine labeled protein. Anomalous
differences were extracted with XPREP (Bruker Analyti-
cal X-ray Solutions) and selenium atoms were located
with SHELXD [28]. Phasing was achieved in SHARP
[29] and the correct hand was discerned after solvent
flattening with SOLOMON [30] and DM [31] from the
CCP4 suite [32]. Bones were edited in O [16] and used
to superimpose a similar structure that had previously
been identified with PHYRE [33]. This was then used to
derive a monomer mask and NCS operators using
MAMA [34], LSQMAN [35] and IMP from the RAVE
package [32]. After overlap removal with NCSMASK
from the CCP4 suite, DM was employed for 4-fold
NCS-averaging, which greatly improved the quality of
the electron density map. The model was traced in O
[36] and COOT [37]. REFMAC5 [38] was employed for
maximum likelihood refinement, defining each single
chain as a TLS body.
The high-resolution EhpR/GA complex was solved by
molecular replacement with MOLREP [39], using a
dimer of the apo structure as search model. Refinement
followed a similar procedure as for the apo form, using
ligand restraints dictionaries generated with PRODRG
[40] for REFMAC5 and with eLBOW [41] for phenix.
refine [38]. phenix.refine was employed for the final
rounds of refinement, which included the determination
of anisotropic displacement parameters. The restraints
for griseoluteic acid were tightened to preserve the geo-
metry of the ligand in the course of refinement with
phenix.refine.
Figures were prepared with PyMOL [41].
Full data collection and refinement statistics are pro-
vided in Table 1.
Stopped flow experiments
Association kinetics of EhpR with griseoluteic acid were
observed at 25°C in a stopped flow apparatus (Applied
Photophysics) by following changes in the tryptophan
fluorescence of the protein (lex = 298 nm; lem > 320
nm (cut-off filter)) for 1 second. EhpR was applied at a
final concentration of 5 μM, the concentration of GA
was varied between 250 and 500 μM. Both protein and
ligand were dissolved in 50 mM TRIS-HCl pH 7.5, 5
mM MgCl2. Individual stopped-flow traces were fitted
to a single exponential to obtain pseudo first-order rate
constants (kobs). While these experiments demonstrated
that EhpR and GA interact, no linear relationship
between ligand concentration and kobs was observed. As
a consequence, it was not possible to determine the affi-
nity or the association rate constant of the reaction.
Microscale thermophoresis measurements
His6-tagged EhpR at a concentration of 118 μM was
labeled with fluorescein isothionate (FITC) at a protein:
reagent ratio of 1:0.9 in 0.1 M Na2CO3 pH 9.3 at 298 K
for one hour. Unreacted FITC was removed with a
NAP5 sephadex column (GE Healthcare) primed with
0.1 M TRIS-HCl pH 8.5, resulting in a label/protein
ratio of 0.8.
A series of 15 1:2 dilutions from 4 mM to 122 nM GA
in 25 nM FITC-EhpR solution was prepared and ther-
mophoresis at 298 K was measured for 30 s in a Mono-
lith NT.115 device (NanoTemper Technologies GmbH),
using 100% infrared laser power. Data of three indepen-
dent runs were averaged and fitted to a hyperbolic func-
tion using Grafit (Erithacus Software).
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